{"altmetric_id":898604,"counts":{"readers":{"mendeley":42,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":1,"unique_users":["190850978249"],"posts_count":1},"total":{"posts_count":1}},"citation":{"abstract":"Standard treatment for latent tuberculosis infection (LTBI) is 9 months daily isoniazid (9INH). An alternative is 4 months daily rifampin (4RMP), associated with better completion and less toxicity; however, its efficacy remains uncertain.","abstract_source":"pubmed","altmetric_jid":"4f6fa61e3cf058f610007a18","authors":["Esfahani K","Aspler A","Menzies D","Schwartzman K"],"doi":"10.5588\/ijtld.10.0575","first_seen_on":"2012-08-22T00:50:19+00:00","issns":["1027-3719"],"issue":"10","journal":"The International Journal of Tuberculosis and Lung Disease","last_mentioned_on":1328492307,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22283892"],"pmid":"22283892","pubdate":"2012-02-01T00:00:00+00:00","publisher_subjects":[{"name":"Cardiovascular Medicine And Haematology","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["pulmonarymedicine"],"title":"Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.","type":"article","volume":"15","mendeley_url":"http:\/\/www.mendeley.com\/research\/potential-costeffectiveness-rifampin-vs-isoniazid-latent-tuberculosis-implications-future-clinical-t"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":3630112,"mean":4.9307700568987,"rank":2899777,"this_scored_higher_than_pct":2,"this_scored_higher_than":79229,"rank_type":"exact","sample_size":3630112,"percentile":2},"similar_age_3m":{"total_number_of_other_articles":74856,"mean":5.0426107541246,"rank":55261,"this_scored_higher_than_pct":1,"this_scored_higher_than":441,"rank_type":"exact","sample_size":74856,"percentile":1},"this_journal":{"total_number_of_other_articles":521,"mean":2.1304730769231,"rank":394,"this_scored_higher_than_pct":2,"this_scored_higher_than":11,"rank_type":"exact","sample_size":521,"percentile":2},"similar_age_this_journal_3m":{"total_number_of_other_articles":21,"mean":1.63,"rank":12,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":21,"percentile":1}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":2,"Student  > Doctoral Student":5,"Researcher":14,"Student  > Ph. D. Student":6,"Student  > Postgraduate":2,"Student  > Master":4,"Other":6,"Student  > Bachelor":1,"Lecturer":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":22,"Social Sciences":5,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":5,"Business, Management and Accounting":1,"Mathematics":3,"Unspecified":3,"Environmental Science":1,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"mendeley":{"CA":1,"US":2,"BR":1,"GB":3,"CH":1,"IN":1}}},"posts":{"facebook":[{"title":"Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for fut","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=243720839041932&id=190850978249","citation_ids":[898604],"posted_on":"2012-02-06T01:38:27+00:00","summary":"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22283892","author":{"name":"Unidad de Infectolog\u00eda y Medicina Geogr\u00e1fica - Hospital Guillermo Almenara","url":"https:\/\/www.facebook.com\/190850978249","facebook_wall_name":"Unidad de Infectolog\u00eda y Medicina Geogr\u00e1fica - Hospital Guillermo Almenara","image":"https:\/\/graph.facebook.com\/190850978249\/picture","id_on_source":"190850978249"}}]}}